ClinicalTrials.gg
Active, not recruitingNCT05483868Updated Aug 6, 2026

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

A Phase 1 interventional study of AU-011 and AU-011 in Combination with Medical Laser Adminstration in Non-muscle-invasive Bladder Cancer, NMIBC and Non-Muscle Invasive Bladder Carcinoma, sponsored by Aura Biosciences. Active, not recruiting at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Aura Biosciences · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
55
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States — 39 open to participants now, 60 under way, 15 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · United States.

Planned enrollment
47th of 93
55 · median 55
Started
2022
with 8 others
Phase 1
20 of 114
5 open now
Primary completion
2027-03
later than 16 of 59 live
Registered
62nd of 114
by date

Among the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, this one is the 47th largest by planned enrollment of the 93 interventional ones that give a count, is one of 9 that started in 2022, is one of 20 in phase 1, reaches primary completion later than 16 of the 59 other live ones, and was the 62nd registered.

Non-Muscle Invasive Bladder Neoplasms

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

39 of the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer utilizing focal injections with or without laser application.

Read the detailed description

Aura is enrolling participants with urothelial carcinoma to evaluate the safety, technical feasibility, and preliminary efficacy of bel-sar. The goal is to achieve the trial objectives with minimal disruption to the standard of care (SoC) of the treating Investigator.

03

Conditions studied

  • Non-muscle-invasive Bladder Cancer
  • NMIBC
  • Non-Muscle Invasive Bladder Carcinoma
  • Non-Muscle Invasive Bladder Neoplasms
  • Non-Muscle Invasive Bladder Urothelial Carcinoma
  • Urothelial Carcinoma Bladder

Keywords

  • NMIBC
  • TURBT
  • Intramural
  • Belzupacap Sarotalocan
  • Intratumoral
  • urothelial
  • bladder cancer
  • bel-sar
  • AU-011
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet the following histopathologic requirements for urothelial carcinoma:

    • For Cohorts 1b, 4a-c:

    histopathological diagnosis of NMIBC (any grade) is required. For participants with first diagnosis of NMIBC, confirmation of urothelial carcinoma by recent (≤6 months of Screening Visit) is required. Participants with recurrent NMIBC must have a current lesion that clinically appears to be NMIBC with histopathologic confirmation based on TURBT or biopsy within the last 24 months).

    For Cohorts 4d, 4e, 4g and 4h, a diagnosis of LG IR NMIBC (according to

    AUA risk classification guidelines) is required, specifically:

    • Multifocal LG Ta; OR
    • Solitary LG Ta >3 cm; OR
    • Low-grade Ta with prior recurrence(s) within 1 year.

    For Cohorts 4f and 4i, a diagnosis of HR NMIBC (according to AUA risk classification guidelines) is required, specifically:

    • Ta HG papillary disease with or without CIS; OR
    • T1 papillary disease with or without CIS
    • Participants may be BCG-naïve or may have received prior treatment with BCG for HR or IR NMIBC (BCG-exposed, BCG-failed, BCG-intolerant)
    • BCG- participants are excluded. BCG-refractory is defined by the following:

      • Persistent HG disease at 6 months following adequate BCG (defined as ≥5/6 induction instillations and ≥2 additional doses, either from re-induction or maintenance), OR
      • HG T1 disease at first evaluation (3 months) after BCG, OR
      • Persistent CIS that remains despite a second BCG course, OR
      • Disease progression in stage or grade during BCG therapy, including maintenance
  2. Have no evidence of current or prior urothelial carcinoma
  3. Adequate bone marrow, renal, and hepatic function

Exclusion criteria

Exclusion Criteria:

  1. Any additional that requires active treatment, unless deemed appropriate after discussion by the Investigator with the trial's Medical Monitor.
  2. Used an drug or medical device within 30 days or 5 half-lives (whichever is longer) of Visit 1 or be concurrently enrolled in another investigational trial.
  3. Active bacterial, fungal, or viral infections - all prior infections must have resolved following optimal therapy and subject must be off all systemic anti-infective agents.
  4. Active disease, chronic inflammatory condition, or other conditions (like solid organ transplant or bone marrow allograft) requiring concurrent use of any systemic or .
  5. Chronic active or C and .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Focal injections of AU-011 prior to TURBT (1b)

    Intratumoral (50 μg) and intramural (50 μg) injection of AU-011 prior to the standard of care (TURBT) in patients with NMIBC.

    Drug: AU-011

  • Experimental
    Focal injections of AU-011 with laser application before TURBT (4a)

    Intratumoral (50 μg) and intramural (50 μg) injection of AU-011 with laser application before standard of care (TURBT) in patients with NMIBC.

    Combination Product: AU-011 in Combination with Medical Laser Adminstration

  • Experimental
    Focal injection of AU-011 with laser application before TURBT (4b)

    Focal injection of AU-011 (100 μg) with laser application before standard of care (TURBT) in patients with NMIBC.

    Combination Product: AU-011 in Combination with Medical Laser Administration

  • Experimental
    Focal injection of AU-011 with laser application before TURBT (4c)

    Focal injection of AU-011 (200 μg) with laser application before standard of care (TURBT) in patients with NMIBC.

    Combination Product: AU-011 in Combination with Medical Laser Administration

  • Experimental
    Focal injection of AU-011 and laser application with option for TURBT (4d)

    Participants with intermediate-risk NMIBC will receive multiple treatment cycles of focal AU-011 (200 ug per lesion) with laser treatment and option for TURBT in patients with intermediate risk NMIBC. Participants will be evaluated for safety and response to AU-011 up to 12 months from initiation of treatment.

    Combination Product: AU-011 in Combination with Medical Laser Administration

  • Experimental
    Focal injection of AU-011 and laser application with option for TURBT (4e)

    Participants with intermediate-risk NMIBC will receive multiple treatment cycles of focal AU-011 (400 µg per lesion) followed by laser activation, with the option for TURBT. Participants will be evaluated for safety and response to AU-011 for up to 12 months from initiation of treatment. Enrollment will occur in parallel with Cohort 4g, with randomized (1:1) assignment.

    Combination Product: AU-011 in Combination with Medical Laser Administration

  • Experimental
    Focal injection of AU-011 and laser application with mandatory TURBT (4f)

    Participants with high-risk NMIBC will receive multiple treatment cycles of focal AU-011 (400 µg per lesion) followed by laser activation prior to mandatory TURBT. Participants will be evaluated for safety and response to AU-011 for up to 12 months from initiation of treatment.

    Combination Product: AU-011 in Combination with Medical Laser Administration

  • Experimental
    Focal injection of AU-011 and laser application with optional TURBT (4g)

    Participants with intermediate-risk NMIBC will receive multiple treatment cycles of focal AU-011 (400 µg per lesion) followed by laser activation with the option of TURBT. Participants will be evaluated for safety and response to AU-011 for up to 12 months from initiation of treatment. Enrollment will occur in parallel with Cohort 4e, with randomized (1:1) assignment.

    Combination Product: AU-011 in Combination with Medical Laser Administration

  • Experimental
    Focal injection of AU-011 and laser application with option for TURBT (4h)

    Participants with intermediate-risk NMIBC will receive multiple treatment cycles of focal AU-011 (800 ug per lesion) with laser treatment and option for TURBT. Participants will be evaluated for safety and response to AU-011 up to 12 months from initiation of treatment. This arm is optional and will be run at the discretion of the sponsor.

    Combination Product: AU-011 in Combination with Medical Laser Administration

  • Experimental
    Focal injection of AU-011 and laser application with mandatory TURBT (4i)

    Participants with high-risk NMIBC will receive multiple treatment cycles of focal AU-011 (800 µg per lesion) before mandatory TURBT. Participants will be evaluated for safety and response to AU-011 up to 12 months from initiation of treatment. This arm is optional and will be run at the discretion of the sponsor.

    Combination Product: AU-011 in Combination with Medical Laser Administration

Interventions

06

What researchers measure

Primary outcomes

  1. Safety of AU-011: Incidences of SAEs and DLTs

    Incidence and severity of treatment-related adverse events \[time frame 12 months\], serious adverse events \[time frame 12 months\], and incidence of dose-limiting toxicities \[time frame 14 days\]

    Time frame: up to 12 months

Secondary outcomes

  1. Complete response (CR) rate

    for all cohorts

    Time frame: at the 3-month time point and at TURBT

  2. Duration of response (DoR)

    In participants who achieve CR

    Time frame: 12 months

  3. Durable CR rate

    Proportion of participants maintaining a CR after achieving a CR

    Time frame: 6-, 9-, and 12-month follow-up

  4. Recurrence-free survival (RFS)

    Participants in neoadjuvant cohorts

    Time frame: 12 mos

07

Study locations

19 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Mar 2027, 54 months after the start.

Of 24 phase 1 interventional studies under Non-Muscle Invasive Bladder Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 61. This study's planned 54 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2022
First posted
Aug 2, 2022
StartActual
Sep 26, 2022
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05483868
Lead sponsor
Aura Biosciences
Responsible party
Sponsor
First posted
Aug 2, 2022
Start date
Sep 26, 2022
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Aug 6, 2026

Study contacts

Medical Monitor
study director · Aura Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belzupacap sarotalocan

Start the discussion